MyFinsight
Home
Blog
About
Cash and cash
equivalents
$19,889,960
(91.92%↑ Y/Y)
Prepaid clinical trial
costs
$849,721
(713.54%↑ Y/Y)
Prepaid expenses and
other current assets
$400,909
(15.55%↑ Y/Y)
Total current assets
$21,140,590
(95.47%↑ Y/Y)
Total assets
$21,140,590
(81.70%↑ Y/Y)
Total liabilities and
stockholders equity
$21,140,590
(81.70%↑ Y/Y)
Total stockholders'
equity
$15,207,245
(3412.06%↑ Y/Y)
Total liabilities
$5,933,345
(-50.94%↓ Y/Y)
Accumulated deficit
-$189,781,770
(-7.37%↓ Y/Y)
Additional paid-in capital
$204,976,637
(16.27%↑ Y/Y)
Total current
liabilities
$5,933,345
(-50.87%↓ Y/Y)
Common stock, par value
of 0.0001...
$12,378
(82.03%↑ Y/Y)
Accrued clinical
expenses
$2,588,464
(-52.68%↓ Y/Y)
Accounts payable
$2,456,152
(-50.57%↓ Y/Y)
Accrued compensation
$497,462
(-17.45%↓ Y/Y)
Other accrued
liabilities
$247,174
(-73.21%↓ Y/Y)
Short-term debt
$144,093
(27.24%↑ Y/Y)
Back
Back
Balance Sheet
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
source: myfinsight.com